

European Drug Utilisation Research Group (EuroDURG)

First published: 18/08/2013

Last updated: 18/11/2013

Network

Network identification

PURI

<https://redirect.ema.europa.eu/resource/5175>

Network ID

5175

Network countries

- Austria
- Belgium
- Croatia
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Hungary

- Iceland
 - Ireland
 - Italy
 - Lithuania
 - Netherlands
 - Norway
 - Poland
 - Portugal
 - Slovenia
 - Spain
 - Sweden
 - United Kingdom
-

Network website

<https://www.pharmacoepi.org/eurodurg>

ENCePP partner

Yes

Network description

The constitution of EuroDURG was accepted by a General Assembly in 1996 at Balatonaliga. Since 2010 EuroDURG functions as the European branch of the Special Interest Group of Drug Utilization Research (SIG-DUR) within the International Society for Pharmacoepidemiology (ISPE). Aims: Encourage communication and cooperation between scientists in several disciplines interested in DU research Work towards the adoption of standards for international and national DU research methodology. Maximise the potential of the information available on DU for improving patient care Promote the incorporation of DU research and its applications in educational programmes. Encourage health policy personnel to use drug utilisation studies to

enhance the future quality and efficiency of prescribing.

Activities&publications:Organize scientific meetings,educational sessions.

Participate in research projects. Identify and communicate with individual DU researchers. Publish a yearly Bulletin.

Network details

Network primary therapeutic area:

- Cardiovascular diseases
 - Disorders of the central nervous system
 - Endocrine disorders
 - Gastrointestinal tract
 - Geriatrics
 - Infectious diseases
 - Musculoskeletal and joint diseases
 - Psychiatry
-

Network funding:

- • Other

Contact

Ria Benko



benkoria@gmail.com

Björn Wettermark



bjorn.wettermark@ki.se